Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cassava Sciences Inc
SAVA | US
1.59
USD-0.03
-1.85%
SAVA | US
About Cassava Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
1.59
Open
1.62
High
1.65
Low
1.57
Cassava Sciences Inc. a clinical stage biotechnology company develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam a small molecule drug which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics Inc. and changed its name to Cassava Sciences Inc. in March 2019. The company was incorporated in 1998 and is based in Austin Texas.
View LessSAVA | US
Risk
42.7
Sharpe
0.31
Luna's Score
30/100
Recommendation
Sell
Luna says (SAVA | US)
What's Working
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Short percentage (> 15%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
34.5%1 month
42.7%3 months
78.4%6 months
84.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
151.51
Price to book
7.36
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-8.26
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-130.64M
MarketCap
76.28M
MarketCap(USD)
76.28M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-8.35
Short ratio
9.57
Short perc.
39.21
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.23
Range1M
0.33
Range3M
0.92
Volumes: Market Activity
Rel. volume
1.81
Price X volume
1.01M
